The Fanconi anemia/BRCA pathway is involved in DNA interstrand cross-link repair of adriamycin-resistant leukemia cells

References

• Saffi J, Agnoletto MH, Guecheva TN, et al. Effect of the anti-neoplastic drug doxorubicin on XPD-mutated DNA repair-deficient human cells. DNA Repair (Amst) 2010;9:40–47.
   PubMed Web of Science ®Google Scholar
• Moldovan GL, D’Andrea AD. How the fanconi anemia pathway guards the genome. Annu Rev Genet 2009;43:223–249.
   PubMed Web of Science ®Google Scholar
• Kim H, D’Andrea AD. Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway. Genes Dev 2012;26:1393–1408.
   PubMedGoogle Scholar
• Romick-Rosendale LE, Lui VW, Grandis JR, et al. The Fanconi anemia pathway: repairing the link between DNA damage and squamous cell carcinoma. Mutat Res 2013;743–744:78–88.
   PubMed Web of Science ®Google Scholar
• D’Andrea AD. Targeting DNA repair pathways in AML. Best Pract Res Clin Haematol 2010;23:469–473.
   PubMed Web of Science ®Google Scholar
• Ciccia A, Ling C, Coulthard R, et al. Identification of FAAP24, a Fanconi anemia core complex protein that interacts with FANCM. Mol Cell 2007;25:331–343.
   PubMed Web of Science ®Google Scholar
• Ling C, Ishiai M, Ali AM, et al. FAAP100 is essential for activation of the Fanconi anemia-associated DNA damage response pathway. EMBO J 2007;26:2104–2114.
   PubMed Web of Science ®Google Scholar
• Leveille F, Blom E, Medhurst AL, et al. The Fanconi anemia gene product FANCF is a flexible adaptor protein. J Biol Chem 2004;279:39421–39430.
   PubMed Web of Science ®Google Scholar
• Garcia-Higuera I, Kuang Y, Denham J, et al. The fanconi anemia proteins FANCA and FANCG stabilize each other and promote the nuclear accumulation of the Fanconi anemia complex. Blood 2000;96:3224–3230.
   PubMed Web of Science ®Google Scholar
• Gordon SM, Buchwald M. Fanconi anemia protein complex: mapping protein interactions in the yeast 2- and 3-hybrid systems. Blood 2003;102:136–141.
   PubMed Web of Science ®Google Scholar
• de Winter JP, van der Weel L, de Groot J, et al. The Fanconi anemia protein FANCF forms a nuclear complex with FANCA, FANCC and FANCG. Hum Mol Genet 2000;9:2665–2674.
   PubMedGoogle Scholar
• Ueda F, Sumi K, Tago K, et al. Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs. Cell Signal 2013;25:2115–2124.
   PubMed Web of Science ®Google Scholar
• Chen Q, Van der Sluis PC, Boulware D, et al. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood 2005;106:698–705.
   PubMedGoogle Scholar
• Xiao H, Xiao Q, Zhang K, et al. Reversal of multidrug resistance by curcumin through FA/BRCA pathway in multiple myeloma cell line MOLP-2/R. Ann Hematol 2010;89:399–404.
   PubMed Web of Science ®Google Scholar
• Chen CC, Taniguchi T, D’Andrea A. The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents. J Mol Med (Berl) 2007;85:497–509.
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Tischkowitz M, Ameziane N, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003;9:568–574.
   PubMed Web of Science ®Google Scholar
• Mathew CG. Fanconi anaemia genes and susceptibility to cancer. Oncogene 2006;25:5875–5884.
   PubMed Web of Science ®Google Scholar
• Crossan GP, Patel KJ. The Fanconi anaemia pathway orchestrates incisions at sites of crosslinked DNA. J Pathol 2012;226:326–337.
   PubMed Web of Science ®Google Scholar
• Knipscheer P, Raschle M, Smogorzewska A, et al. The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair. Science 2009;326:1698–1701.
   PubMed Web of Science ®Google Scholar
• Kuraoka I, Kobertz WR, Ariza RR, et al. Repair of an interstrand DNA cross-link initiated by ERCC1-XPF repair/recombination nuclease. J Biol Chem 2000;275:26632–26636.
   PubMed Web of Science ®Google Scholar
• Niedzwiedz W, Mosedale G, Johnson M, et al. The Fanconi anaemia gene FANCC promotes homologous recombination and error-prone DNA repair. Mol Cell 2004;15:607–620.
   PubMed Web of Science ®Google Scholar
• Yarde DN, Oliveira V, Mathews L, et al. Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res 2009;69:9367–9375.
   PubMedGoogle Scholar
• Rothfuss A, Grompe M. Repair kinetics of genomic interstrand DNA cross-links: evidence for DNA double-strand break-dependent activation of the Fanconi anemia/BRCA pathway. Mol Cell Biol 2004;24:123–134.
   PubMed Web of Science ®Google Scholar
• Wang X, Li DH. Adriamycin-induced apoptosis of tumor cells: research progress. China Pract Med 2010;7:247–249.
   Google Scholar
• Lundholm L, Haag P, Zong D, et al. Resistance to DNA-damaging treatment in non-small cell lung cancer tumor-initiating cells involves reduced DNA-PK/ATM activation and diminished cell cycle arrest. Cell Death Dis 2013;4:478.
   PubMed Web of Science ®Google Scholar
• Wha JD, Hwang M, Kim HJ, et al. Ouabain, a cardiac glycoside, inhibits the Fanconi anemia/BRCA pathway activated by DNA interstrand cross-linking agents. PLoS One 2013;8:75905.
   Web of Science ®Google Scholar